3-(4-hydroxyphenyl)-2-phenylpropionic acid ethyl ester | 197299-09-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-hydroxyphenyl)-2-phenylpropionic acid ethyl ester
• 英文别名: ethyl 3-(4-hydroxyphenyl)-2-phenoxypropionate；ethyl 3-(4-hydroxyphenyl)-2-phenoxypropanoate
• CAS: 197299-09-5
• 化学式: C₁₇H₁₈O₄
• 分子量: 286.328
• InChiKey: SWORFEYAXCYOMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-hydroxyphenyl)-2-phenylpropionic acid ethyl ester 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 为溶剂， 生成 Ethyl 3-(3-bromo4-hydroxyphenyl)-2-phenoxypropionate
  参考文献：
  名称：

  Amidocarboxylic acid derivatives

  摘要：

  公式为：其中R1代表氢原子，等等；R2代表烷基团；R3代表氢原子，等等；R4代表氢原子，等等；X代表取代或未取代的芳基团，等等；Y代表氧原子，等等；Z代表烷基团，等等；W代表烷基团，等等；以及其药理学上可接受的盐和药理学上可接受的酯作为药物组合物的活性成分是有用的。它们可用于治疗特定疾病，包括糖尿病、高脂血症、动脉硬化、高血压等。

  公开号：

  US06528525B1
• 作为产物：
  描述：

  ethyl 3-(4-benzyloxyphenyl)lactate 在 palladium on activated charcoal 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 18.0h， 生成 3-(4-hydroxyphenyl)-2-phenylpropionic acid ethyl ester
  参考文献：
  名称：

  Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents

  摘要：

  We previously reported the identification of novel oximes having 5-benzyl-2,4-thiazolidinedione with anti hyperglycemic activity. We now report the synthesis and biological activity of a novel series of oximes and amides having alpha-substituted-beta-phenylpropionic acids. In this series, we obtained potent PPARalpha/gamma dual agonist (S)-9d, with which activation of PPARalpha and PPARgamma was considerably more potent than that of the reference compounds GW9578 22 and rosiglitazone 3, respectively. This means (S)-9d is of the strongest class of PPARalpha/gamma dual agonists. In the course of this study, we also obtained 8h, which indicated potent plasma glucose lowering effect in spite of weak PPARalpha/gamma agonistic activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.01.048

文献信息

• Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids:  A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists
  作者：Yanping Xu、Christopher J. Rito、Garret J. Etgen、Robert J. Ardecky、James S. Bean、William R. Bensch、Jacob R. Bosley、Carol L. Broderick、Dawn A. Brooks、Samuel J. Dominianni、Patric J. Hahn、Sha Liu、Dale E. Mais、Chahrzad Montrose-Rafizadeh、Kathy M. Ogilvie、Brian A. Oldham、Mary Peters、Deepa K. Rungta、Anthony J. Shuker、Gregory A. Stephenson、Allie E. Tripp、Sarah B. Wilson、Leonard L. Winneroski、Richard Zink、Raymond F. Kauffman、James R. McCarthy

  DOI：10.1021/jm0342616

  日期：2004.5.1

  The design and synthesis of the dual peroxisome proliferator activated receptor (PPAR) alpha/gamma agonist (S)-2-methyl-3-[4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)ethoxy]phenyl]-2-pheno xypropionic acid (2) for the treatment of type 2 diabetes and associated dyslipidemia are described. 2 possesses a potent dual hPPAR alpha/gamma agonist profile (IC(50) = 28 and 10 nM; EC(50) = 9 and 4 nM, respectively

  双过氧化物酶体增殖物激活受体（PPAR）α/γ激动剂（S）-2-甲基-3- [4- [2-（5-甲基-2-噻吩-2-基-恶唑-4）的设计与合成描述了用于治疗2型糖尿病和相关血脂异常的（-基）乙氧基]苯基] -2-苯氧基丙酸（2）。2具有有效的双重hPPARα/γ激动剂特性（对于hPPARalpha和hPPARgamma，IC（50）= 28和10 nM； EC（50）= 9和4 nM）。在临床前模型中，2可显着改善胰岛素敏感性，并有效逆转糖尿病性高血糖症，同时显着改善总体脂质体内平衡。
• Phenylalkylcarboxylic acid compounds and compositions for treating
  申请人：Sankyo Company, Limited

  公开号：US06103907A1

  公开（公告）日：2000-08-15

  Phenylalkylcarboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 represents an alkyl group and the like, R.sup.2 represents an alkylene group, R.sup.3 represents a hydrogen atom and the like, X represents a substituted or unsubstituted aryl group and the like, Y represents an oxygen atom and the like, Z represents an alkylene group and the like, and W represents an alkyl group and the like), the pharmacologically acceptable salts thereof or the pharmacologically acceptable esters thereof are useful as therapeutic or preventive agents for hyperglycemia and the like.

  公式为：##STR1## 的苯基烯基羧酸化合物，其中 R.sup.1 代表烷基等，R.sup.2 代表亚烷基等，R.sup.3 代表氢原子等，X 代表取代或未取代的芳基等，Y 代表氧原子等，Z 代表亚烷基等，W 代表烷基等），其药理学上可接受的盐或其药理学上可接受的酯对治疗或预防高血糖等方面有用。
• Amidocarboxylic acid compounds
  申请人：SANKYO COMPANY, LTD

  公开号：US20040006141A1

  公开（公告）日：2004-01-08

  Amidocarboxylic acid compounds of the formula: 1 wherein R 1 represents hydrogen or alkyl; R 2 represents alkylene; R 3 represents hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro, dialkylamino, aryl, aralkyl, hydroxyl or acyl; R 4 represents hydrogen or alkyl; X represents an aryl or hetero aryl; Y represents a single bond, oxygen, sulfur or N—R 5 , wherein R 5 is hydrogen, alkyl, aliphatic acyl or aromatic acyl; Z represents alkylene; and W represents alkyl, hydroxyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, aralkyl, aralkyloxy, aralkylthio, aryloxyalkyl, hetero aryl, hetero aryloxy, hetero alkylthio, heterocyclic, amino, alkylamino, N-alkyl-N-arylamino, arylamino, aralkylamino or aralkyloxycarbonylamino. The compounds are used to treat diabetes mellitus, hyperlipemia, arteriosclerosis, obesity, impaired glucose tolerance, insulin-resistant non-IGT, fatty liver, diabetic complications, gestational diabetes mellitus, polycystic ovary syndrome, atherosclerosis, arthrosteitis, rheumatic arthritis, allergic diseases, asthma, cancer, autoimmune diseases, pancreatitis and cataracts.

  公式为1的羧酸类化合物：其中R1代表氢或烷基；R2代表亚烷基；R3代表氢、烷基、烷氧基、烷硫基、卤素、硝基、二烷基氨基、芳基、芳基烷基、羟基或酰基；R4代表氢或烷基；X代表芳基或杂芳基；Y代表单键、氧、硫或N-R5，其中R5为氢、烷基、脂肪族酰基或芳香族酰基；Z代表亚烷基；W代表烷基、羟基、烷氧基、烷硫基、芳基、芳氧基、芳硫基、芳基烷基、芳基烷氧基、芳基烷硫基、芳氧基烷基、杂芳基、杂芳氧基、杂烷硫基、杂环、氨基、烷基氨基、N-烷基-N-芳基氨基、芳基氨基、芳基烷基氨基或芳基烷氧羰基氨基。这些化合物用于治疗糖尿病、高脂血症、动脉硬化、肥胖症、糖耐量受损、胰岛素抵抗非IGT、脂肪肝、糖尿病并发症、妊娠期糖尿病、多囊卵巢综合症、动脉粥样硬化、关节炎、类风湿性关节炎、过敏性疾病、哮喘、癌症、自身免疫性疾病、胰腺炎和白内障。
• PHENYLALKYLCARBOXYLIC ACID DERIVATIVES
  申请人：Sankyo Company, Limited

  公开号：EP0916651A1

  公开（公告）日：1999-05-19

  Phenylalkylcarboxylic acid derivatives of the general formula: wherein R1 represents an alkyl group and the like, R2 represents an alkylene group, R3 represents a hydrogen atom and the like, X represents a substituted or unsubstituted aryl group and the like, Y represents an oxygen atom and the like, Z represents an alkylene group and the like, and W represents an alkyl group and the like), the pharmacologically acceptable salts thereof or the pharmacologically acceptable esters thereof are useful as therapeutic or preventive agents for hyperglycemia and the like.

  通式如下的苯基烷基羧酸衍生物 其中 R1 代表烷基等，R2 代表亚烷基等，R3 代表氢原子等，X 代表取代或未取代的芳基等，Y 代表氧原子等，Z 代表亚烷基等，W 代表烷基等）、 其药理学上可接受的盐类或其药理学上可接受的酯类可用作高血糖等的治疗或预防剂。
• AMIDOCARBOXYLIC ACID DERIVATIVES
  申请人：Sankyo Company Limited

  公开号：EP1026149A1

  公开（公告）日：2000-08-09

  Amidocarboxylic acid derivatives of the formula: [wherein R1 represents a hydrogen atom, etc.; R2 represents an alkylene group; R3 represents a hydrogen atom, etc; R4 represents a hydrogen atom, etc., X represents a substituted or unsubstituted aryl group, etc.; Y represents an oxygen atom, etc.; Z represents an alkylene group, etc.; and W represents an alkyl group, etc.], pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof are useful as a therapeutic agent and/or preventive agent for diabetes mellitus, hyperlipemia, arteriosclerosis, hypertension, etc.

  式中的氨基甲酸衍生物： [其中 R1 代表氢原子等；R2 代表亚烷基等；R3 代表氢原子等；R4 代表氢原子等；X 代表取代或未取代的芳基等；Y 代表氧原子等；Z 代表亚烷基等；W 代表烷基等]及其药理学上可接受的盐和药理学上可接受的酯可用作糖尿病、高脂血症、动脉硬化、高血压等的治疗剂和/或预防剂。